GlassScriptPhysician profile
Jeffrey David Welder
NPI 1043504681
$3,911.51
in general payments reported to CMS, 2019-2025
29 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $348 · 2021: $683 · 2022: $321 · 2023: $451 · 2024: $465 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132 · Entertainment: $23.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.38 |
| Entertainment | $23.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $920.45 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $578.31 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $479.51 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $377.99 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $317.27 | 2019-2024 | Eylea Hd, Eylea |
| Biotissue Holdings INC. | $222.01 | 2019-2021 | |
| Genentech USA, INC. | $204.91 | 2022-2025 | Vabysmo |
| Ivantis, INC | $105.13 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $83.08 | 2019-2021 | |
| Horizon Therapeutics Plc | $75.20 | 2021-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $63.97 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Astellas Pharma US INC | $61.24 | 2023-2025 | Izervay |
| Oyster Point Pharma, INC. | $57.13 | 2023-2024 | Tyrvaya |
| Merz Pharmaceuticals, LLC | $50.90 | 2022-2023 | Xeomin |
| Dompe US, INC. | $32.73 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.33 | 2024 | Tepezza |
| Allergan, INC. | $25.85 | 2021-2022 | |
| Iridex Corporation | $25.44 | 2019 | |
| Merz North America, INC. | $23.87 | 2019 | |
| Optos, INC. | $23.78 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $22.82 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $18.51 | 2023 | Syfovre |
| Sandoz INC. | $18.50 | 2024 | Cimerli |
| Kala Pharmaceuticals, INC. | $17.89 | 2021 | |
| Glaukos Corporation | $17.67 | 2022 | |
| Tearlab Corp | $14.10 | 2021 | |
| Biogen, INC. | $13.92 | 2024 | Byooviz |
| Sight Sciences, INC. | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Welder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.